Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.2%

2 terminated out of 48 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

23%

11 trials in Phase 3/4

Results Transparency

11%

2 of 18 completed with results

Key Signals

2 with results90% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (9)
Early P 1 (1)
P 2 (7)
P 3 (4)
P 4 (7)

Trial Status

Completed18
Recruiting13
Unknown11
Not Yet Recruiting3
Terminated2
Active Not Recruiting1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (48)

Showing 20 of 20 trials
NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07500467CompletedPrimary

Upadacitinib for Refractory Takayasu Arteritis

NCT07477795Phase 2Not Yet RecruitingPrimary

Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients

NCT07491913Not ApplicableRecruitingPrimary

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

NCT02967068Recruiting

VCRC Tissue Repository

NCT03482479Phase 2Completed

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

NCT07351422RecruitingPrimary

Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis

NCT06887062Phase 2Recruiting

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

NCT07325357Phase 4Not Yet RecruitingPrimary

Effect of Pirfenidone on TA Fibrosis

NCT07276087RecruitingPrimary

Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls

NCT07149805CompletedPrimary

Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta

NCT06979245CompletedPrimary

Turkish Adaptation of the VascuQoL-6 Quality of Life Scale

NCT07077304Not Yet Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

NCT05168475Phase 2Terminated

Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

NCT04882072Phase 3TerminatedPrimary

A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)

NCT02981979Not ApplicableCompletedPrimary

Takayasu Arteritis Clinical Trial in China

NCT05904301Recruiting

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

NCT06662721Phase 2CompletedPrimary

Baricitinib for Refractory Takayasu Arteritis

NCT06498089Phase 4RecruitingPrimary

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

NCT05102448Phase 4RecruitingPrimary

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Scroll to load more

Research Network

Activity Timeline